CHS Pharma is an emerging biotechnology company committed to the development of an innovative treatment for a precancerous skin condition commonly known as Actinic Keratosis.

We anticipate a substantial opportunity for company expansion and growth through the development of new treatment, as evidenced in laboratory research conducted by Dr. Herbert Weissbach. With a strategic business plan for product development and launch, an expert management and research team, and tangible opportunities for expansion, CHS Pharma has the necessary resources for successful market saturation.